

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT8247288

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	MEDIVATION LLC	02/12/2018
RECEIVING PARTY DATA		
Name:	MEDIVATION PROSTATE THERAPEUTICS LLC	
Street Address:	525 MARKET STREET	
City:	SAN FRANCISCO	
State/Country:	CALIFORNIA	
Postal Code:	94105	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Application Number:	17985235
CORRESPONDENCE DATA		
Fax Number:		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Email:	bwptopat@bannerwitcoff.com	
Correspondent Name:	BANNER & WITCOFF, LTD.	
Address Line 1:	1100 13TH ST. NW	
Address Line 4:	WASHINGTON, D.C. 20005	
ATTORNEY DOCKET NUMBER:	006810.00380\US	
NAME OF SUBMITTER:	LISA M. HEMMENDINGER	
SIGNATURE:	/Lisa M. Hemmendinger/	
DATE SIGNED:	10/30/2023	
Total Attachments: 5		
source=Assignment_MedivationLLC_to_MPTLLC#page1.tif		
source=Assignment_MedivationLLC_to_MPTLLC#page2.tif		
source=Assignment_MedivationLLC_to_MPTLLC#page3.tif		
source=Assignment_MedivationLLC_to_MPTLLC#page4.tif		
source=Assignment_MedivationLLC_to_MPTLLC#page5.tif		

ASSIGNMENT

For valuable consideration, the receipt and adequacy of which is hereby acknowledged, Medivation LLC ("Assignor") (formerly Medivation, Inc.), a limited liability company organized and existing under the laws of the State of Delaware, United States of America, having its principal place of business at 525 Market Street, San Francisco, CA 94105, hereby assigns and transfers unto Medivation Prostate Therapeutics LLC ("Assignee") (formerly Medivation Prostate Therapeutics, Inc.), a limited liability company organized and existing under the laws of the State of Delaware, United States of America, having its principal place of business at 525 Market Street, San Francisco, CA 94105, all of its entire right, title and interest in and to the patents and patent applications (whether provisional or otherwise) listed in Schedule A, attached hereto and incorporated herein (the "Patents"), including, without limitation, (i) any inventions and improvements disclosed and claimed therein, and any continuations, continuations-in-part (but only to the extent the claims thereof are entitled to the benefit of the parent priority date), divisions, reissues, reissuances, revisions, reexaminations, counterparts, extensions or available foreign equivalents thereof (to the extent that a deadline for a filing has not passed without such filing having being made), (ii) all corresponding rights that are or may be secured under the laws of the United States or any foreign country, now or hereafter arising or in effect, and (iii) all rights to apply for, prosecute and obtain patents in respect of any of the inventions to the extent fully supported by the Patents in any country of the world, including the right to claim priority from said Patents under the Paris Convention for the Protection of Industrial Property, and under any and all other such treaties and agreements to which the United States is a party and which afford similar priority-claiming privileges, in all countries of the world, all Letters Patent or extension

certificates which may be granted thereon for Assignee's own use and enjoyment, and for the use and enjoyment of Assignee's successors, assigns, or other legal representatives, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment had not been made; as well as the right to sue in the name of Assignee and recover damages for past infringement of any patent application or patent assigned hereby;

And Assignor hereby agrees, whenever requested, to communicate to Assignee and its successors and assigns, any facts known to it respecting said inventions, to testify in any legal proceeding respecting said inventions, and to execute all applications or papers necessary to obtain and maintain proper patent protection on said inventions in all countries of the world;

And Assignor authorizes Assignee or its designee to supply any missing patent application or patent identification information or correct any errors in the patent application or patent identification information provided herein whether discovered prior to or after recordation;

And Assignor hereby appoints Assignee, through its designee, its attorney-in-fact to execute, in its name and on its behalf, any and all documents required to effectuate this Assignment, including but not limited to further assignments, corrective assignments, powers of attorney and other papers.

IN WITNESS WHEREOF, Assignor has caused this Assignment to be executed by their duly authorized representatives as of Feb 12, 2018


Assignor: Medivation LLC



Name: Matthew J. Pugmire


Title: Attorney-in-Fact

Witness:


Victoria Summers

February 12, 2018

Witness:


Janice Sanchez

February 12, 2018

*** NOTARIZATION REQUIRED ***

A notary public or other officer completing this certificate verifies only the identity of the individual who signed the document to which this certificate is attached, and not the truthfulness, accuracy, or validity of that document.

STATE of California

COUNTY of San Diego

On February 12, 2018 before me, Jessica Ann Conen, Notary Public,
Date

Here Insert Name

and Title of the Officer


personally appeared Matthew J. Pugmire
Name of Signer


who proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing paragraph is true and correct.

WITNESS my hand and official seal.

Signature


Signature of Notary Public



Place Notary Seal Above

IN WITNESS WHEREOF, Assignee has caused this Assignment to be executed by their duly authorized representatives as of February 12, 2018

Assignee: Medivation Prostate
Therapeutics LLC

Name: Stephen D. Prodnuk
Title: Attorney-in-Fact

Witness:

Victoria Summers
February 12, 2018

Witness:

Rebecca Jenkins
February 12, 2018

*** NOTARIZATION REQUIRED ***

A notary public or other officer completing this certificate verifies only the identity of the individual who signed the document to which this certificate is attached, and not the truthfulness, accuracy, or validity of that document.

STATE of California

COUNTY of San Diego

On February 12, 2018 before me, Janice Sanchez, Notary Public,
Date Here Insert Name and Title of the Officer

personally appeared Stephen D. Prodnuk
Name of Signer

who proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing paragraph is true and correct.
WITNESS my hand and official seal.

Signature

Janice Sanchez
Signature of Notary Public



Place Notary Seal Above

Schedule A - Schedule Of Patents

Country	Application Number	Application Date	Patent Number	Grant Date	Title
Australia	*2013315619	09/11/2013			Formulations Of Enzalutamide
Brazil	BR112015005432-3	09/11/2013			Formulations Of Enzalutamide
Canada	*2884795	09/11/2013			Formulations Of Enzalutamide
China P.R.	*201380055471.6	09/11/2013			Formulations Of Enzalutamide
Eurasian Patent Convention	*201500314	09/11/2013			Formulations Of Enzalutamide
European Patent Convention	*13766437.1	09/11/2013			Formulations Of Enzalutamide
Hong Kong	*15100714.7	01/22/2016			Formulations Of Enzalutamide
India	2875/DELNP/2015	09/11/2013			Formulations Of Enzalutamide
Indonesia	P00201502062	09/11/2013			Formulations Of Enzalutamide
Israel	*237604	09/11/2013			Formulations Of Enzalutamide
Japan	2015-531335	09/11/2013			Formulations Of Enzalutamide
Japan	2016-176557	09/09/2016			Formulations Of Enzalutamide
Korea South	10-2015-7009040	09/11/2013			Formulations Of Enzalutamide
Mexico	MX/a/2015/003140	09/11/2013			Formulations Of Enzalutamide
Patent Cooperation Treaty	PCT/US2013/059223	09/11/2013			Formulations Of Enzalutamide
Philippines	1/2015/500525	09/11/2013			Formulations Of Enzalutamide
South Africa	2015/01847	09/11/2013	2015/01847	01/27/2016	Formulations Of Enzalutamide
Taiwan	*102132800	09/11/2013			Formulations Of Enzalutamide
Thailand	*1501001321	09/11/2013			Formulations Of Enzalutamide
Ukraine	a201503119	09/11/2013			Formulations Of Enzalutamide
United States	61/699351	09/11/2012			Formulations Of Enzalutamide
United States	14/023537	09/11/2013			Formulations Of Enzalutamide
United States	14/023878	09/11/2013			Formulations Of Enzalutamide
United States	14/481986	09/10/2014			Formulations Of Enzalutamide
United States	15/018076	02/08/2016			Formulations Of Enzalutamide
United States	15/267352	09/16/2016			Formulations Of Enzalutamide

PATENT

RECORDED: 10/30/2023

REEL: 065383 FRAME: 0840